TürkiyeResearch and clinical trials
At Hacettepe, 3 children with the same SAMHD1 change showed very different symptoms
The SAMHD1 gene causes one type of Aicardi-Goutières syndrome.
Neuromuscular diseases
An inherited disease that affects the brain, the immune system and the skin. It usually begins in infancy. Brain development is affected.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Neuromuscular diseases” group.
The cells cannot clear away pieces of DNA and RNA that are no longer useful. The body mistakes them for viruses. The immune system works when it does not need to, and substances called interferons increase. This inflammation damages the brain, the skin and other organs.
In the early type, symptoms begin in the first months. In the late type, the baby first develops normally, and symptoms appear after the age of one.
A brain CT scan shows calcium deposits, and an MRI shows changes in the white matter. White blood cells and interferon may be increased in the cerebrospinal fluid. The diagnosis is confirmed with a genetic test.
There is not yet a treatment that fully cures the disease. Many specialists work together on care. This includes nutritional support, chest physiotherapy and treatment of seizures. Medicines that suppress the immune response are being researched. The eyes, thyroid and spine are checked regularly. The doctor who follows the disease decides which treatment is suitable.
It is usually passed on through recessive inheritance. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Recessive diseases can be more common when relatives marry each other. With some genes, dominant inheritance or a new gene change is also seen. Genetic counselling clarifies the family's risk.
Source: MedlinePlus Genetics: Aicardi-Goutières syndrome · GeneReviews: Aicardi-Goutières Syndrome · NORD: Aicardi-Goutières Syndrome
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
TürkiyeResearch and clinical trials
The SAMHD1 gene causes one type of Aicardi-Goutières syndrome.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
InternationalResearch and clinical trials
The HIMALAYA study, published in The Lancet Neurology, examined an experimental drug in patients with ALS (amyotrophic lateral sclerosis).
TürkiyeResearch and clinical trials
A multicenter study in Istanbul compared patients with Guillain-Barré syndrome.
USANew treatments and approvals
The US Food and Drug Administration (FDA) approved levacetylleucine for balance and walking problems in ataxia-telangiectasia (A-T).
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:51
No separate ICD-11 code; WHO classifies this disease under: 5C55.2
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.